BioWorld

Nov. 8, 2006

Inovio, Wyeth Enter Potential $64.5M Pact On Drug Delivery

Wyeth juiced Inovio Biomedical Corp.'s bottom line with a potential $64.5 million, nonexclusive licensing deal that gives the pharma giant rights to use MedPulser electroporation delivery technology in DNA vaccines. (BioWorld Today) Read More

Pharma Growing Biologics Work To Supplement Small Molecules

Studying Cell Division, Without Cells, Yields Novel BRCA1 Role

Cytogen Bringing In $20M For Product Launch, Clinical Work

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 10, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026